Tumor cells and antigen-presenting cells (cellular tropism)

This entry refers to a therapeutic strategy defined by cellular tropism toward tumor cells and antigen-presenting cells (APCs) rather than a specific molecular receptor or enzyme. This approach is most commonly associated with oncolytic immunotherapy, where agents like modified viruses are designed to selectively infect and lyse malignant cells while simultaneously engaging the host immune system (Source: NIH, National Cancer Institute). By infecting tumor cells, these agents cause direct cellular destruction and the release of tumor-derived antigens into the microenvironment. The involvement of APCs, such as dendritic cells and macrophages, is crucial for the subsequent uptake of these antigens and the priming of T-cell-mediated immune responses (Source: PubMed, PMID: 28533413). Consequently, the target is a functional cellular profile that facilitates both local tumor debulking and the induction of a systemic in situ vaccine effect. This strategy bypasses the need for a single high-affinity molecular target, instead relying on the differential biological properties of cancerous versus healthy tissue (Source: Nature Reviews Cancer). Drugs utilizing this tropism often incorporate transgenes, such as GM-CSF, to further enhance the recruitment and activation of APCs at the site of the tumor. This dual-action mechanism aims to overcome the immunosuppressive nature of the tumor microenvironment.

Other names

Tumor and APC tropismDual cellular tropismOncolytic viral tropismCellular tropism, no defined molecular target

Selective viral replication and oncolysis in tumor cells combined with the stimulation of antigen-presenting cells to trigger a systemic anti-tumor immune response.